FDA approves combo for mesothelioma, atezolizumab strikes out, and more

Tuesday, October 13, 2020

Hematology-Oncology News:

  1. Radiotherapy planning scans reveal breast cancer patients’ CVD risk (https://bit.ly/2FeoJiH)
  2. FDA OKs combination immunotherapy for first-line mesothelioma treatment (https://bit.ly/2Ff77mS)
  3. Apatinib plus gefitinib: Better PFS but more toxicity (https://bit.ly/34IyVsn)
  4. Atezolizumab strikes out in ovarian cancer (https://bit.ly/3iPjXG1)

Email Blood & Cancer at [email protected] and learn more at https://www.mdedge.com/podcasts/blood-cancer

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.